<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520036</url>
  </required_header>
  <id_info>
    <org_study_id>MT-7117-A01</org_study_id>
    <nct_id>NCT03520036</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria</brief_title>
  <official_title>A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Development America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Development America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of MT-7117 on sunlight&#xD;
      exposure duration without symptoms and tolerance in subjects with EPP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, randomized, double-blind, placebo controlled study to assess the efficacy,&#xD;
      tolerability, and safety of MT-7117 in subjects with EPP. The study consists of a 2 week&#xD;
      screening period, a 16 week double-blind treatment period, and a 6 week follow-up period at&#xD;
      Week 22. The total participation period is approximately 24 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 5, 2018</start_date>
  <completion_date type="Actual">September 28, 2019</completion_date>
  <primary_completion_date type="Actual">September 28, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in average daily duration of sunlight exposure without symptoms</measure>
    <time_frame>Baseline (Week 0) and Week 16</time_frame>
    <description>Duration in minutes, of sunlight exposure between 1 hour post sunrise and 1 hour pre-sunset</description>
  </primary_outcome>
  <other_outcome>
    <measure>Total number of sunlight exposure episodes</measure>
    <time_frame>Baseline (Week 0) and Week 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in pigmentation as measured by melanin density</measure>
    <time_frame>Baseline (Week 0) and Week 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The quality of life as measured by the Patient Reported Outcomes Measurement Information System (PROMIS) 57</measure>
    <time_frame>Baseline (Week 0) and Week 16</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Erythropoietic Protoporphyria (EPP)</condition>
  <arm_group>
    <arm_group_label>MT-7117 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-7117 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-7117 low dose</intervention_name>
    <description>MT-7117 low dose QD, oral, 16 weeks</description>
    <arm_group_label>MT-7117 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-7117 high dose</intervention_name>
    <description>MT-7117 high dose QD, oral, 16 weeks</description>
    <arm_group_label>MT-7117 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo QD, oral, 16 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Additional screening criteria check may apply for qualification.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Subjects provided written informed consent to participate.&#xD;
&#xD;
          -  2. Male and female subjects with a confirmed diagnosis of EPP based on medical&#xD;
             history, aged 18 years to 75 years, inclusive, at Screening.&#xD;
&#xD;
          -  3. Subjects are willing and able to travel to the study sites for all scheduled&#xD;
             visits.&#xD;
&#xD;
          -  4. In the Investigator's opinion, subject is able to understand the nature of the&#xD;
             study and any risks involved in participation, and willing to cooperate and comply&#xD;
             with the protocol restrictions and requirements (including travel).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. History or presence of photodermatoses other than EPP.&#xD;
&#xD;
          -  2. Subjects who are unwilling or unable to go outside during daylight hours (e.g.,&#xD;
             between 1 hour post sunrise and 1 hour pre-sunset) during the study.&#xD;
&#xD;
          -  3. Presence of clinically significant hepatobiliary disease based on LFT values at&#xD;
             Screening.&#xD;
&#xD;
          -  4. Subjects with AST, ALT, ALP ≥3.0 × upper limit of normal (ULN) or total bilirubin&#xD;
             &gt;1.5 × ULN at Screening.&#xD;
&#xD;
          -  5. Subjects with or having a history (in the last 2 years) of excessive alcohol intake&#xD;
             in the opinion of the Investigator.&#xD;
&#xD;
          -  6. History or presence of melanoma and/or atypical nevus at Screening.&#xD;
&#xD;
          -  7. History of familial melanoma (defined as having 2 or more first-degree relatives,&#xD;
             such as parents, sibling and/or child).&#xD;
&#xD;
          -  8. History or presence of pre-malignant skin lesion squamous cell carcinoma, basal&#xD;
             cell carcinoma, or other malignant skin lesions.&#xD;
&#xD;
          -  9. History or presence of psychiatric disease judged to be clinically significant by&#xD;
             the Investigator and which may interfere with the study evaluation and/or safety of&#xD;
             the subjects.&#xD;
&#xD;
          -  10. Presence of clinically significant acute or chronic renal disease based upon the&#xD;
             subject's medical records including hemodialysis; and a serum creatinine level of&#xD;
             greater than 1.2 mg/dL or a glomerular filtration rate (GFR) &lt;60 ml/min.&#xD;
&#xD;
          -  11. Presence of any clinically significant disease or laboratory abnormality which, in&#xD;
             the opinion of the Investigator, can interfere with the study objectives and/or safety&#xD;
             of the subjects.&#xD;
&#xD;
          -  12. Pregnancy or lactation.&#xD;
&#xD;
          -  13. Females of child bearing potential and male subjects with partners of&#xD;
             child-bearing potential unwilling to use adequate contraception measures as described&#xD;
             in the protocol.&#xD;
&#xD;
          -  14. Treatment with phototherapy within 3 months before Randomization (Visit 2).&#xD;
&#xD;
          -  15. Treatment with afamelanotide within 3 months before Randomization (Visit 2).&#xD;
&#xD;
          -  16. Treatment with cimetidine within 4 weeks before Randomization (Visit 2).&#xD;
&#xD;
          -  17. Treatment with antioxidant agents at doses which, in the opinion of the&#xD;
             Investigator, may affect study endpoints (including but not limited to beta-carotene,&#xD;
             cysteine, pyridoxine) within 4 weeks before Randomization (Visit 2).&#xD;
&#xD;
          -  18. Chronic treatment with prescription-based analgesic agents including but not&#xD;
             limited to opioids and opioid derivatives such as morphine, hydrocodone, oxycodone or&#xD;
             their combination with other analgesics or non-steroidal anti-inflammatory drug&#xD;
             (NSAID, as Percocet and Vicodin-like prescription drugs) within 4 weeks before&#xD;
             Randomization (Visit 2).&#xD;
&#xD;
          -  19. Treatment with any drugs or supplements which, in the opinion of the Investigator,&#xD;
             can interfere with the objectives of the study or safety of the subjects.&#xD;
&#xD;
          -  20. Previous exposure to MT 7117.&#xD;
&#xD;
          -  21. Previous treatment with any investigational agent within 12 weeks before Screening&#xD;
             OR 5 half-lives of the investigational product (whichever is longer).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head of Clinical Development,</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Development America, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ACTCA, A Member of the Alliance, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Boston Clinical Partners, LLC</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ichan School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Remington-Davis, Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch Porphyria Center</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 23, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <disposition_first_submitted>September 24, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>September 24, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 30, 2020</disposition_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protoporphyria, Erythropoietic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

